

Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026
Earnings Conference Call to be Held on March 24, 2026



Hong Kong, March. 12, 2026 -- Sisram Medical Ltd (the “**Company**” or “**Sisram**”, 1696.HK; together with its subsidiaries collectively referred to as the “**Group**”), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that it will report its audited consolidated results for the year ended December 31, 2025 on Monday March 23, 2026.

The Company’s management will host earnings conference calls on Tuesday, March 24, 2026, to discuss the financial results. Management team will deliver prepared remarks followed by a question-and-answer session.

Speakers will include:

Mr. Lior Moshe Dayan	Chairman
Mr. Eyal Ben David	CEO
Mr. Jiahong Li	Co-CEO and CFO
Ms. Qianli Fang	Secretary of the Board
Ms. Hui Fan	Investor Relations Director

Participants who wish to join the conference calls are invited to complete the online registration via the link or by scanning the QR codes below prior to the scheduled call start time:

	Chinese Session	English Session
Date/Time	March 24, 2026 15:30 - 16:30 HKT	March 24, 2026 20:00 - 21:00 HKT 8:00 - 9:00 ET 14:00 - 15:00 IST
Phone Number/ Conference ID	400 810 8228	821 6369 9780
Passcode	771989	701014
Registration Link	https://www.comein.cn/roadshow/home/478578	https://cls.zoom.com/webinar/register/WN_cwIJ0WGRQWmOyoiZdv-euw
QR Code		

For participants joining the English session, a confirmation email with detailed instructions for accessing the webinar will be sent upon successful registration.

A replay of the conference calls will be available on the Company's website under the investor relations section shortly after the events: www.sisram-medical.com.

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company's synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

For more information, please visit: www.sisram-medical.com.

For Investor Relations inquiries, please contact:

IR@sisram-medical.com